Phase 3 N=1,383 Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=861 Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Allergic Conjunctivitis
Primary: Ocular Comfort — 0.13; 0.07; 0.06; 0.02 Scores on a scale
Phase 3 N=10 Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
HIV
Primary: Proportion of Patients Who Maintain Plasma HIV Viral Load Measurements < 400 Copies/ml at 2, 4, 8, 12, 16, 24, 36 and 48 Weeks After Switching to DRV/r and ETR, Missing…
Phase 3 N=287 The CLEVER Study - Coreg And Left Ventricular Mass Regression
Hypertrophy, Left Ventricular
Primary: Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12…
Phase 3 N=504 Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Treatment Failure — 184; 141 participants — p=<0.0001
Phase 3 N=654 The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
Hypertension
Primary: Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure — -5.79; -8.11; -7.37; -4.40 mmHg — p=>0.1
Phase 3 N=108 Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
Generalized Anxiety Disorder
Primary: Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free — 20; 10…
Phase 3 N=848 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Chemotherapy-Induced Nausea and Vomiting
Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01
Phase 3 N=488 Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
Sleep Initiation and Maintenance Disorders
Primary: Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2). — 67.0; 41.7 minutes — p=<0.001
Phase 3 N=542 Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Dyslipidemias · Coronary Heart Disease · Combined (Atherogenic) Dyslipidemia
Primary: Median Percent Change in Triglycerides From Baseline to Final Visit — -57.3; -39.7 Percent change — p=< 0.001
Phase 3 N=619 E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Heartburn
Primary: Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population — 100; 121 Participants
Phase 3 N=2,773 AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
Renal Failure
Primary: Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) — 396; 408 Participants
Phase 3 N=312 The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score — -22.4; -18.4 Change in total score at endpoint — p=0.022
Phase 3 N=442 Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
Diabetes Mellitus Type 2
Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.79; 8.77; -1.52; -1.31 percent of HbA1c — p=0.026
Phase 3 N=471 Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — 8.70; 8.69; -1.46; -1.41 percent of HbA1c — p=0.551